Kukje Pharma Co., Ltd. (KRX:002720)
South Korea
· Delayed Price · Currency is KRW 4,920.00
+45.00 (0.92%)
Mar 10, 2026, 9:40 AM KST
Kukje Pharma Revenue
Kukje Pharma had revenue of 45.63B KRW in the quarter ending September 30, 2025, with 15.09% growth. This brings the company's revenue in the last twelve months to 173.80B, up 15.77% year-over-year. In the year 2024, Kukje Pharma had annual revenue of 156.46B with 15.58% growth.
Revenue (ttm)
173.80B
Revenue Growth
+15.77%
P/S Ratio
0.57
Revenue / Employee
700.79M
Employees
248
Market Cap
99.27B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 156.46B | 21.09B | 15.58% |
| Dec 31, 2023 | 135.37B | 8.79B | 6.94% |
| Dec 31, 2022 | 126.58B | 6.84B | 5.71% |
| Dec 31, 2021 | 119.75B | -10.65B | -8.17% |
| Dec 31, 2020 | 130.39B | 19.27B | 17.34% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CKD Bio | 159.93B |
| Enzychem Lifesciences | 72.17B |
| Ildong Holdings | 620.44B |
| Kyongbo Pharmaceutical | 252.20B |
| Jeil Pharma Holdings | 707.15B |
| HANDOK | 516.37B |
| Yuyu Pharma | 139.51B |
| Whan In Pharm | 256.32B |